These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31014988)

  • 1. Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged.
    Alabraba E; Joshi H; Bird N; Griffin R; Sturgess R; Stern N; Sieberhagen C; Cross T; Camenzuli A; Davis R; Evans J; O'Grady E; Palmer D; Diaz-Nieto R; Fenwick S; Poston G; Malik H
    Eur J Surg Oncol; 2019 Sep; 45(9):1660-1667. PubMed ID: 31014988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy.
    Robertson JM; Lawrence TS; Dworzanin LM; Andrews JC; Walker S; Kessler ML; DuRoss DJ; Ensminger WD
    J Clin Oncol; 1993 Jul; 11(7):1286-93. PubMed ID: 8391066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure to administer multimodality therapy leads to sub-optimal outcomes for patients with node-positive biliary tract cancers in the United States.
    Sheka AC; Altman A; Marmor S; Hui JYC; Denbo JW; Ankeny JS; Jensen EH
    Surg Oncol; 2020 Sep; 34():298-303. PubMed ID: 32891346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality from hepatocellular and biliary cancers: changing epidemiological trends.
    Nair S; Shiv Kumar K; Thuluvath PJ
    Am J Gastroenterol; 2002 Jan; 97(1):167-71. PubMed ID: 11808943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
    DeLeon TT; Ahn DH; Bogenberger JM; Anastasiadis PZ; Arora M; Ramanathan RK; Aqel BA; Vasmatzis G; Truty MJ; Oklu R; Bekaii-Saab TS; Borad MJ
    Future Oncol; 2018 Mar; 14(6):553-566. PubMed ID: 29460642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification and implementation of NCCN guidelines on hepatobiliary cancers in the Middle East and North Africa region.
    Yusuf MA; Kapoor VK; Kamel RR; Kazmi A; Uddin N; Masood N; Al-Abdulkareem A;
    J Natl Compr Canc Netw; 2010 Jul; 8 Suppl 3():S36-40. PubMed ID: 20697130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical Treatments of Hepatobiliary Cancers.
    Gunasekaran G; Bekki Y; Lourdusamy V; Schwartz M
    Hepatology; 2021 Jan; 73 Suppl 1():128-136. PubMed ID: 32438491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century.
    Pulte D; Weberpals J; Schröder CC; Emrich K; Holleczek B; Katalinic A; Luttmann S; Sirri E; Jansen L; Brenner H;
    Int J Cancer; 2018 Jul; 143(2):324-332. PubMed ID: 29479701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia: Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014.
    Loho IM; Hasan I; Lesmana CR; Dewiasty E; Gani RA
    Asian Pac J Cancer Prev; 2016; 17(4):2165-70. PubMed ID: 27221913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The State of Immunotherapy in Hepatobiliary Cancers.
    Ilyas FZ; Beane JD; Pawlik TM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996.
    Cance WG; Stewart AK; Menck HR
    Cancer; 2000 Feb; 88(4):912-20. PubMed ID: 10679662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-disciplinary Concurrent Management of Recurrent Hepatocellular Therapy is Superior to Sequential Therapy.
    Fields TD; Philips P; Scoggins CR; Tatum C; Kelly L; McMasters KM; Martin RCG
    World J Surg; 2017 May; 41(5):1331-1339. PubMed ID: 27905019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW
    Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review.
    Glantzounis GK; Tokidis E; Basourakos SP; Ntzani EE; Lianos GD; Pentheroudakis G
    Eur J Surg Oncol; 2017 Jan; 43(1):32-41. PubMed ID: 27283892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Right portal vein embolization with absolute ethanol in major hepatic resection for hepatobiliary malignancy.
    Sofue K; Arai Y; Shimada K; Takeuchi Y; Kobayashi T; Satake M; Sugimura K
    Br J Surg; 2014 Aug; 101(9):1122-8. PubMed ID: 24920297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Patt YZ; Hassan MM; Aguayo A; Nooka AK; Lozano RD; Curley SA; Vauthey JN; Ellis LM; Schnirer II; Wolff RA; Charnsangavej C; Brown TD
    Cancer; 2004 Aug; 101(3):578-86. PubMed ID: 15274071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
    Ruff SM; Shannon AH; Pawlik TM
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.
    von Hahn T; Ciesek S; Wegener G; Plentz RR; Weismüller TJ; Wedemeyer H; Manns MP; Greten TF; Malek NP
    Scand J Gastroenterol; 2011 Sep; 46(9):1092-8. PubMed ID: 21692710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma in a low-endemic area: rising incidence and improved survival.
    Witjes CD; Karim-Kos HE; Visser O; van den Akker SA; de Vries E; Ijzermans JN; de Man RA; Coebergh JW; Verhoef C
    Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):450-7. PubMed ID: 22273986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease.
    Castro FA; Liu X; Försti A; Ji J; Sundquist J; Sundquist K; Koshiol J; Hemminki K
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1038-45.e7. PubMed ID: 24246767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.